Sign In
Buy MMIRF
$0.0121
+0 (+0%)
At Close: Jun 03, 2026
MedMira Reports Second Quarter Results FY2025
10:00pm, Wednesday, 01'st Apr 2026
HALIFAX, NS / ACCESS Newswire / April 1, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2026. Corporate update In Q2 FY2026, the Co
MedMira Reports First Quarter Results FY2026
08:00pm, Tuesday, 30'th Dec 2025
HALIFAX, NOVA SCOTIA / ACCESS Newswire / December 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2025. Corporate update In Q1 F
MedMira Reports FY2025 Fourth Quarter and Year End Financial Results
09:00pm, Friday, 28'th Nov 2025
HALIFAX, NOVA SCOTIA / ACCESS Newswire / November 28, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2025. Corporate update In
Health Canada Approves MedMira's Reveal(R) Rapid TP Test - Urgent New Tool In The Battle Against Syphilis
04:43pm, Tuesday, 26'th Aug 2025
HALIFAX, NOVA SCOTIA / ACCESS Newswire / August 26, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received approval from Health Canada for its Reveal® TP (Syphilis) Antibody Te
MedMira Announces Launch of Clinical Trial for Its Multiplo(R) TP/HIV Self-Test in Canada
07:00am, Monday, 07'th Jul 2025
HALIFAX, NS / ACCESS Newswire / July 7, 2025 / MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started earlier than anticipated to evaluate M
MedMira Reports Second Quarter Results FY2025
11:00pm, Monday, 30'th Jun 2025
HALIFAX, NS / ACCESS Newswire / June 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2025. Corporate update In Q3 FY2025, MedMir
MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense
06:00am, Thursday, 17'th Apr 2025
HALIFAX, NS / ACCESS Newswire / April 17, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as
MedMira Reports Second Quarter Results FY2025
10:00pm, Tuesday, 01'st Apr 2025
HALIFAX, NS / ACCESS Newswire / April 1, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2025. Corporate update In Q2 FY2025, MedMir
MedMira Announces Partnership with MediGroup Physician Services in the United States
04:30pm, Thursday, 27'th Feb 2025
HALIFAX, NS / ACCESS Newswire / February 27, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today its partnership with MediGroup, a leader in the US health care industry since 1999. This new partn
MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada
06:00pm, Tuesday, 25'th Feb 2025
HALIFAX, NS / ACCESS Newswire / February 25, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today its exclusive distribution agreement with Trimedic Inc. for the Canadian market. This partnership
MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications
06:00pm, Tuesday, 21'st Jan 2025
HALIFAX, NS / ACCESS Newswire / January 21, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clin
MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use
05:00pm, Tuesday, 14'th Jan 2025
HALIFAX, NS / ACCESSWIRE / January 14, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test (Reveal
MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
06:00pm, Thursday, 09'th Jan 2025
HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trial
MedMira Reports First Quarter Results FY2025
10:00pm, Monday, 30'th Dec 2024
HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2024. Corporate update During Q1 FY2025, Med
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
12:00pm, Tuesday, 24'th Dec 2024
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Ra
